Objectives: Light chains κ and λ are immunoglobulin constituents but also circulate independently in blood as free light chains. We investigated whether a concomitant abnormality in free light chain and immunoglobulin levels could identify a high risk of death sepsis subpopulation to inform future IV immunoglobulin trials. We tested whether light chain allelic inclusion occurs in circulating B cells.
treatment responsive subpopulations (2) (3) (4) . Studies that help to enrich sepsis subpopulations based on abnormalities in immunoglobulin (Ig) biology could inform future IVIg trial design, as new trials are being planned (5) . We recently tested whether low IgG levels on the day of sepsis diagnosis identified a higher risk of death subpopulation (6) . Despite a high prevalence of low IgG levels, this abnormality alone did not identify mortality risk.
In health, circulating Ig consists of heavy chains bound by disulfide bonds to either κ or λ light chains. These light chains are also measurable as circulating free light chains (FLCs), separate from Ig molecules. Raised FLC levels are associated with sepsis risk factors such as low-grade inflammation, increasing age, and renal dysfunction (7) (8) (9) . Altered FLC concentrations have been reported in a pilot study performed on 21 ICU patients with sepsis (10) .
Since reduced Ig and raised FLC concentrations are both associated with sepsis, we investigated whether their concomitant abnormality could enrich a sepsis population for IVIg trials (Table 1) (11, 12) . Ideally, enrichment markers should forecast the likely patient outcome irrespective of baseline risk and should also have biological plausibility (6, 11) . Several observations highlight such plausibility for concomitant FLC and Ig abnormalities in sepsis, in addition to the known associations of FLCs described above (7) (8) (9) (10) . In health, excess light chains are present in the perinuclear space to prevent intracellular heavy chain aggregation prior to Ig assembly and are secreted as FLC after Ig assembly (13) . Thus, impaired Ig assembly in sepsis could result in raised FLC and low Ig levels (2, 3, 14) . We also considered whether an altered stoichiometry of light chain production could contribute to raised FLC concentrations. Rules of allelic exclusion permit only a single Ig specificity by each B cell. However, we recently reported that acute inflammation in autoimmune diseases can result in simultaneous expression of both κ and λ light chains by a single B cell. Thus, light chain allelic inclusion in the context of acute inflammation may result in production of excess FLC (15) . Against this background, after describing longitudinal changes in FLC and Ig levels in sepsis, we tested whether concomitant abnormalities in FLC and Ig levels on ICU admission day (D1) are independently associated with hospital mortality. We also examined surface κ and λ light chain expression on B cells to ascertain light chain allelic inclusion.
MATERIALS AND METHODS

Study Design and Setting
This prospective observational cohort study was performed in the general medical-surgical ICUs of an university hospital. Ethics committee approval was obtained prior to start of recruitment (10/H0807/81 and 12/LO/0326; Camberwell St Giles Committee, London, United Kingdom). Clinical management was at the discretion of the attending physician.
Study Population
Consecutive patients with sepsis within the first 12 hours following ICU admission between May 2011 and January 2015 were included. Sepsis was identified using the old definition as evidence of two or more systemic inflammatory response syndrome (SIRS) criteria, with proven or suspected infection and at least one organ system dysfunction (cardiovascular, respiratory, renal, hematologic, neurologic, or metabolic) (16) . We excluded patients less than 18 years; those with congenital hypogammaglobulinemia, known protein-losing enteropathies, nephrotic syndrome, and neoplastic or proliferative hematologic diseases; those having received IVIg therapy in the last 3 months; those receiving high-dose corticosteroid therapy; those with ongoing blood loss (defined by blood transfusion requirement > 2 units/24 hr period); those with retroviral disease; and those with immune dysfunction as defined by Acute Physiology and Chronic Health Evaluation (APACHE) II score comorbidities (17) . We have recently published other (27) or impaired IgG recycling (3) or a normal immunoglobulin consumption but with impaired immunoglobulin assembly due to B-cell abnormalities in sepsis (14) . "High" FLC in sepsis could be related to either excess production related to sepsis-related inflammation or due to allelic inclusion of light chains in B cells (13, 15) . Enrichment principles are further explored in these reviews (11, 12) .
details on B-cell changes in sepsis from this population, using the same cohort (14) .
Clinical Data, Blood Sampling, and Flow Cytometry Baseline demographic data, infection details, and variables to record SIRS, APACHE II (17) , and Sepsis-related Organ Failure Assessment (SOFA) scores (18) were collected. Blood samples were collected within 12 hours of ICU entry on D1, on day 3 (D3), and on day 7 (D7) (or on the day of demise or discharge if these events occurred earlier). After clot separation and centrifugation (3,000 revolutions per min; 10 min; 4°C), serum samples were stored at -70°C. Blinded batch analysis was performed for Ig and FLC levels to reduce interassay variation. Ig molecules (total IgG, IgA, and IgM) (Dade Behring Nephelometer; Marburg, Germany) and serum FLC using polyclonal sheep antisera (Freelite; Binding Site, Birmingham, United Kingdom) were analyzed on a special protein analysis system plus analyzer (Binding Site). The FLC ratio (FLCR) was derived as the ratio of FLCκ to FLCλ. Flow cytometry was used to ascertain light chain allelic inclusion in circulating B cells using a Canto-A flow cytometer (Becton Dickinson [BD], Franklin Lakes, NJ). Peripheral blood mononuclear cells were isolated within 4 hours of blood sampling using Ficoll density centrifugation. Antihuman antibodies, clone, and company are reported in parenthesis. Anti-CD19 (PerCP Cy5.5; HB19; BD), anti-κ LC (ACP-H7; G20-193; BD), anti-λ LC (Pacific Blue; MHL-38; BioLegend, San Diego, CA) and Live/ Dead Fixable Aqua (Life Technologies, Paisley, United Kingdom) antibodies were used for cell surface expression of CD19, LC-κ, and LC-λ, respectively. Gating during analysis of flow cytometry standard files was achieved using isotype controls, fluorescence minus one controls, and/or single stain controls.
Derivation of Abnormal Categories
The reference normal ranges for an adult general population in the United Kingdom are IgG (6.1-
mg/L, and FLCR (0.26-1.65). The upper and lower limits of these normal ranges were used to define normal and abnormal categories. These categorizations allowed generation of prevalence data and comparison of the proportions of survivor and nonsurvivor sepsis patients with each abnormality.
Sample Size Estimation
Sample size was estimated using precision estimates for IgG distribution (19) , as IgG is the most often altered Ig in sepsis (6) . One hundred patients were required to achieve a margin of error of 0.74 g/L of IgG measurement based on the population sd of 3.72 g/L observed in the first 30 patients enrolled.
Statistics
Continuous data are presented as mean and sd when normally distributed and as median and interquartile range (IQR) when not. Frequency and percentages are presented for categorical data. Two sets of comparisons described longitudinal changes in FLC. First, we compared proportions of high FLCs and concentrations of FLCs between survivors and nonsurvivors on days 1, 3, and 7. Second, we compared how proportions of high FLCs and temporal changes in concentration varied between survivors and nonsurvivors using paired tests. A similar approach was used to describe changes in Igs.
To report univariate associations and to inform logistic regression models, a pairwise correlation matrix was generated for admission day FLC, FLCR, IgG, IgA, IgM, white cell count, C-reactive protein (CRP), total SOFA score, and APACHE II score. Bonferroni corrections were performed for multiple comparisons. Two analyses were performed to assess any association between a concomitant admission day Ig and FLC abnormality and mortality. Stratified analyses were performed as shown in Table 1 . Two logistic regression models were then used with acute hospital mortality as the outcome: model 1 had high FLCλ, total APACHE II score, hypo-IgG, and hypo-IgM as binary covariates, whereas model 2 had high FLCκ, total APACHE II score, hypo-IgG, and hypo-IgM as binary covariates.
B-cell subsets are reported as a proportion of the live CD19-positive B-cell population. Proportions were compared between healthy controls and sepsis. All analyses were performed using GraphPad Prism version 6.00 (GraphPad Software, La Jolla, CA, www.graphpad.com) and/or Stata/SE Version 13.0 (StataCorp LP, College Station, TX). Reported p values are two sided with p values less than 0.05 representing statistical significance.
RESULTS
Study Cohort
Cohort characteristics by hospital survival status are summarized in Table 2 . Acute hospital mortality was 26.7%. Nonsurvivors were older and had greater illness severity as evidenced by greater APACHE II and SOFA scores. The respiratory tract was the commonest infection site in both survivors and nonsurvivors. In two patients, the site of infection could not be confirmed.
Longitudinal Changes in FLCκ and FLCλ
The prevalence of high FLCκ was similar in survivors and nonsurvivors on D1 (p = 0.45), D3 (p = 0.18), and final sampling day (DF) (p = 0.75). No significant differences were seen in corresponding FLCκ concentrations at any timepoint (Fig. 1A) . The proportion of sepsis patients with abnormal FLCλ was significantly higher in nonsurvivors only on D1 (74.1% vs 36.5%; p = 0.001) but not on D3 (p = 0.24) or DF (p = 0.11). There was an increase in corresponding FLCλ concentrations over time in both survivors and nonsurvivors (p < 0.05). However, when comparing FLCλ concentrations D1, D3, and DF between survivors and nonsurvivors, there were no differences at any timepoint (Fig. 1B) . higher in survivors on D1 (36.5% vs 11.1%, p = 0.01). This ratio decreased on D3 compared with D1 in both survivors and nonsurvivors (p < 0.05) (Fig. 1C) . Analyses restricted to patients with a normal FLCR also showed that the proportion of patients with a high FLCλ was more common in nonsurvivors on D1 (75.0% vs 40.4%; p = 0.007), whereas the proportion with high FLCκ was similar between survivors and nonsurvivors (63.8% vs 83.3%; p = 0.11). ( Fig. 1D) . Similar to IgG concentrations, there were no difference in hypo-IgM by hospital survival status at any timepoint.
Longitudinal Changes in FLCR
Longitudinal Changes in Ig Subtypes
The nadir for IgM was on D3, (p = 0.02 in nonsurvivors) (Fig. 1E) . Hypo-IgA was the least prevalent (6.9%) and observed in only seven survivors (Fig. 1F) .
Associations of FLC and Ig
FLCκ was significantly correlated with FLCλ, FLCR, IgG, and serum creatinine. FLCλ was significantly correlated with FLCκ, IgG, IgA, and serum creatinine. IgG and IgM were significantly correlated. FLCs were not correlated to markers of illness severity (APACHE II and SOFA) nor to acute inflammation (CRP and WBC) (eFig. 1, Supplemental Digital Content 1, http:// links.lww.com/CCM/C766).
High FLCλ Is Associated With Mortality
Using the concept presented in Table 1 , the stratified analyses highlighted higher mortality only in patients with high FLCλ, irrespective of their hypo-IgG or hypo-IgM status ( Fig. 2A and Table  3 ). Hypo-IgA was not included in our logistic regression models assessing high FLC mortality relationship as it occurred only in survivors on day 1. APACHE II score accounted for illness severity and differences in age between survivors and nonsurvivors reported in Table 2 . In "model 1," hospital mortality was significantly associated with the APACHE II score and high FLCλ. The increase in odds ratio (OR) (95% CI) for hospital mortality per unit increase in APACHE II score was 1.2 (1.1-1.4; p < 0.001) and 4.0 (1.3-12.4) for high FLCλ (p = 0.017). In "model 2," hospital mortality was significantly associated only with the APACHE II score; the OR (95% CI) per unit increase in APACHE II score was 1.2 (1.1-1.4; p < 0.001) (eFig. 2, Supplemental Digital Content 1, http://links.lww.com/CCM/C766).
Allelic Inclusion in B Cells and Associations
The gating strategy for identification of light chain allelic inclusion is shown in eFigure 3 (Supplemental Digital Content 1, http://links.lww.com/CCM/C766). The characteristics of the 21 sepsis patient samples used for flow cytometry are summarized in eTable 1 (Supplemental Digital Content 1, http://links.lww. com/CCM/C766). CD19 B cells expressing cell surface LCκ or LCλ, expressed as a proportion of alive CD19 population and as a ratio of CD19κ to CD19λ, were similar in sepsis patients and healthy controls. Septic patients had a significantly higher proportion of CD19 B cells expressing both LCκ and LCλ (CD19 κλ ) Continuous data presented as median and interquartile range when not normally distributed. (Fig. 2B) . A significant correlation existed between the frequencies of these CD19 κλ cells and the corresponding FLC concentrations (Fig.  2C) . A significant correlation was only observed between FLCλ and CD19 B cells expressing cell surface LCλ (Fig. 2C) .
DISCUSSION
High FLCκ, high FLCλ, and high FLCR are common in septic patients admitted to critical care without known immune comorbidities. The presence of a high FLCλ increases the risk of death, even after adjusting for APACHE II score, despite high FLCκ being the more common abnormality. The combination of high FLC and low Igs on ICU D1 was more prevalent in a greater proportion of nonsurvivors. Consistent with the published literature (6), we found that hypo-IgG and hypoIgM were common in sepsis on D1, reaching a nadir on D3, and that more survivors incremented Ig levels over time. These findings increase the external validity of our results.
The approach presented in Table 1 is discussed in the context of our results to inform trial design. IVIg treatment potentially restores normal serum Ig concentrations in patients with low IgG levels, in addition to contributing to immunomodulation (3). In clinical trials, the IVIg treatment effect will vary by the baseline risk of death, referred as heterogeneity in treatment effect (20, 21) . Thus, enriching sepsis patients with a higher risk of death concomitant with a greater likelihood of treatment response inferred by low Igs at admission may be more likely to result in a positive outcome if the strategy is indeed effective (11, 12) . In this study, we position FLCλ as a potential biomarker within the causal pathway from Ig alterations to death in sepsis patients, after accounting for illness severity. High FLCλ identifies a higher risk of death sepsis population. The prevalence of high FLCλ within our sepsis cohort was 46.5%, with 74% of nonsurvivors having this abnormality.
These concepts could be easily validated using data from ongoing trials (5).
We observed major abnormalities in Ig levels without an increase in the risk of death; this finding is consistent with our previous systematic review (6) . Dissecting the relative contributions of altered Ig production, impaired endothelial recycling, and Ig consumption for opsonization during sepsis is challenging due to the lack of a well-characterized regulatory loop for Ig homeostasis (22) . There are no mechanistic studies to date explaining Ig kinetics in sepsis. Our first novel finding is that FLCs are raised with a high FLCλ being associated with an increased risk of hospital mortality after adjustment for illness severity. The kidneys maintain circulating FLC homeostasis via glomerular clearance, proximal tubule endocytosis, and catabolism (23) . Impairments in renal function seen in sepsis could increase FLC concentrations, and this is supported by the positive correlation found between serum FLC and creatinine levels. The increase in FLC could also be due in part to impaired Ig assembly. A pilot study of 21 patients with pneumonia and septic shock found that FLC concentrations did not differ by IgG level (10) . However, this study neither reported longitudinal changes in FLC by survival status nor mechanisms. The FLCR was similar to our cohort, providing further external validity to our results (10) . Important unanswered questions are the mechanisms by which FLC concentrations increase in sepsis and how this affects sepsis biology in terms of illness severity or outcome. The increased proportion of CD19 κλ dual cells in sepsis and their association with raised FLC concentrations is another novel finding that warrants further investigation. In healthy adults, CD19 κλ dual cells represent only 0.5% of circulating B cells (24) ; the rise seen in our sepsis cohort could be a random simultaneous rearrangement of both light chain loci but is most likely to represent allelic inclusion due to impaired κ deleting element activity or a transient phase during light chain revision (24) .
There are several limitations to our study. We have not investigated mechanisms behind these novel findings. We cannot ascertain whether the FLC abnormalities were present before the onset of sepsis nor whether FLCs represent a risk factor for sepsis or mortality irrespective of sepsis (8) . We accounted for these challenges by studying patients without immune comorbidity and by showing the independent effect of high FLCλ on hospital mortality after adjusting for APACHE II score. These novel observations should be replicated in other sepsis cohorts.
As FLC concentrations are linked to Ig assembly in the literature, our findings imply that this FLC-Ig relationship makes FLC a potential biomarker for simultaneous prognostic and predictive enrichment of sepsis patients for IVIg therapy trials (11) . This hypothesis could be confirmed using samples from existing trial data (5) . Further questions raised include the contribution of elevated FLC to renal dysfunction in sepsis, as observed in myeloma patients (23) . Raised FLC levels could also contribute to the prolonged neutrophil life span in sepsis (25) , acting through enhanced tyrosine phosphorylation (26) . The mechanisms involved in B-cell allelic inclusion in sepsis needs exploring.
CONCLUSIONS
In a well-characterized cohort of critically ill adults with sepsis without any immune comorbidity, we report a high prevalence of FLC abnormalities associated with Ig subtype abnormalities and offering prognostic utility. We show evidence of light chain allelic inclusion in B cells. The roles in sepsis pathology and as a putative biomarker for IVIg therapy warrants further study.
